The Pharmacokinetics and Pharmacodynamics of a Hemp-Derived "Full-Spectrum" Oral Cannabinoid Product with a 1:1 Ratio of Cannabidiol to Cannabidiolic Acid and Delta-9-Tetrahydrocannabinol to Delta-9-Tetrahydrocannabinolic Acid: A Double-Blind, Placebo-Controlled, Within-Subjects Human Laboratory Study
MedicinaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Cannabis and cannabinoid research
- Publicado em
- 5 mar 2025
- Citações
- 9
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
The Pharmacokinetics and Pharmacodynamics of a Hemp-Derived "Full-Spectrum" Oral Cannabinoid Product with a 1:1 Ratio of Cannabidiol to Cannabidiolic Acid and Delta-9-Tetrahydrocannabinol to Delta-9-Tetrahydrocannabinolic Acid: A Double-Blind, Placebo-Controlled, Within-Subjects Human Laboratory Study
Harrison J Elder, C Austin Zamarripa, McKenna Klausner, Joseph Wakshlag, Robert Davis, Beth Dresser, Christian Kjaer, Elise M Weerts, Ryan Vandrey, Tory R Spindle
Descritores MeSH
- Cannabidiol
- Cannabinoids
- Plant Extracts
- Dronabinol
- Cannabis
- Humans
- Male
- Administration, Oral
- Young Adult
- Adult
Estudos relacionados
- Impact of CBD and hemp oil use on drug test results: a systematic review
- A randomized clinical trial of low-dose cannabis extract in Alzheimer's disease
- Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting: Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial
- Urinary Excretion Profile of Cannabinoid Analytes Following Acute Administration of Oral and Vaporized Cannabis in Infrequent Cannabis Users